The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas

Yuka Ohmachi,Masaaki Yamamoto,Yuiko Inaba,Shohei Makino,Shin Urai,Risa Matsumoto,Hironori Bando,Keitaro Kanie,Yasutaka Tsujimoto,Yuma Motomura,Yuriko Sasaki,Yuka Oi-Yo,Naoki Yamamoto,Masaki Suzuki,Michiko Takahashi,Genzo Iguchi,Maki Kanzawa,Junya Furukawa,Katsumi Shigemura,Satoshi Mizobuchi,Wataru Ogawa,Hidenori Fukuoka
DOI: https://doi.org/10.1007/s12020-023-03681-4
2024-01-12
Endocrine
Abstract:Preoperative medical management is critical to prevent intraoperative cardiovascular complications in patients with pheochromocytomas and paragangliomas (PPGLs). Initial treatment involves α-adrenergic receptor blockers. However, while the routine use of metyrosine alongside these blockers is not strongly recommended due to a lack of evidence supporting its efficacy and associated safety concerns, there are previous studies on combination therapy with phenoxybenzamine and metyrosine. There are few reports on combination therapy with the selective α1-adrenergic receptor blocker doxazosin. Therefore, we investigated this combination treatment, which theoretically can affect perioperative outcomes in patients with PPGLs. To our knowledge, this is the first such study.
endocrinology & metabolism
What problem does this paper attempt to address?